Use of Sphingosine-1-phosphate (S1P) Receptor Agonists for the Treatment of Brain Degenerative Diseases
1 Assignment
0 Petitions
Accused Products
Abstract
Disclosed is the use of sphingosine-1-phosphate (S1P) receptor agonists, preferably 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol, in the treatment of progressive dementia or brain degenerative diseases
10 Citations
14 Claims
-
1-3. -3. (canceled)
-
4. A pharmaceutical composition for use in treating progressive dementia or brain degeneration, β
- -amyloid-related inflammatory diseases or disorders or for reducing or inhibiting loss of cognitive abilities comprising a sphingosine-1-phosphate (S1P) receptor agonist or a pharmaceutically acceptable salt thereof together with one or more pharmaceutically acceptable diluents or carriers therefore.
- View Dependent Claims (9, 10)
- 5. A pharmaceutical combination comprising a) a first agent which is a S1P receptor agonist or a pharmaceutically acceptable salt thereof and b) a co-agent useful in the alleviation or treatment of brain degenerative diseases or progressive dementia.
-
7. A method for treating progressive dementia or brain degeneration or β
- -amyloid-related inflammatory diseases or disorders or for reducing or inhibiting loss of cognitive abilities in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a sphingosine-1-phosphate (S1P) receptor agonist or a pharmaceutically acceptable salt thereof.
- View Dependent Claims (8, 12, 14)
Specification